Merus (NASDAQ:MRUS) Earns “Buy” Rating from Guggenheim

Merus (NASDAQ:MRUS)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a report released on Tuesday,Benzinga reports. They presently have a $109.00 price objective on the biotechnology company’s stock. Guggenheim’s price target indicates a potential upside of 132.22% from the company’s current price.

A number of other research firms have also recently commented on MRUS. Citigroup increased their target price on shares of Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Bank of America dropped their price objective on shares of Merus from $73.00 to $70.00 and set a “buy” rating for the company in a report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and issued a $85.00 price objective on shares of Merus in a report on Monday, March 3rd. Needham & Company LLC dropped their price objective on shares of Merus from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Wells Fargo & Company began coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective for the company. One investment analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $85.31.

Merus Stock Down 0.6 %

Shares of MRUS stock traded down $0.28 on Tuesday, reaching $46.94. The company had a trading volume of 16,776 shares, compared to its average volume of 631,350. The stock has a market capitalization of $3.24 billion, a PE ratio of -11.88 and a beta of 1.15. Merus has a one year low of $37.77 and a one year high of $61.61. The business’s 50-day moving average is $42.99 and its 200 day moving average is $46.28.

Merus (NASDAQ:MRUS) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.48. The firm had revenue of $9.14 million during the quarter, compared to analysts’ expectations of $10.57 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. On average, sell-side analysts forecast that Merus will post -3.85 earnings per share for the current fiscal year.

Institutional Trading of Merus

Several large investors have recently modified their holdings of the stock. Polar Asset Management Partners Inc. acquired a new stake in shares of Merus during the 4th quarter worth approximately $1,318,000. GF Fund Management CO. LTD. acquired a new stake in shares of Merus during the 4th quarter worth approximately $60,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Merus by 17.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company’s stock worth $4,152,000 after buying an additional 14,544 shares during the period. Woodline Partners LP grew its position in shares of Merus by 0.3% during the 4th quarter. Woodline Partners LP now owns 1,188,518 shares of the biotechnology company’s stock worth $49,977,000 after buying an additional 3,593 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in Merus in the 4th quarter valued at $817,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.